Details of the Drug

General Information of Drug (ID: DMU1LXS)

Drug Name

Trastuzumab Emtansine

Indication

Disease Entry	ICD 11	Status	REF
HER2-positive breast cancer	2C60-2C65	Phase 3	[1]
Breast cancer	2C60-2C65	Phase 2	[1]

Drug Type

Antibody drug conjugate

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 4 days [2]
Vd: The volume of distribution (Vd) of drug is 3.13 L [3]

Cross-matching ID

DrugBank ID: DB05773
TTD ID: D0UG0K
INTEDE ID: DR1629

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[4]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[5]
Aldo-keto reductase 1C3 (AKR1C3)	DEGQTXO	AK1C3_HUMAN	Substrate	[6]
Aldo-keto reductase 1C1 (AKR1C1)	DE7P2FB	AK1C1_HUMAN	Substrate	[6]
Aldo-keto reductase 1C2 (AKR1C2)	DEOY5ZM	AK1C2_HUMAN	Substrate	[6]
Aldo-keto reductase 1C4 (AKR1C4)	DEAJN47	AK1C4_HUMAN	Substrate	[6]
NADPH-dependent carbonyl reductase 3 (CBR3)	DEIVKZ8	CBR3_HUMAN	Substrate	[6]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trastuzumab Emtansine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Trastuzumab Emtansine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[37]
-----------

Coadministration of a Drug Treating the Disease Different from Trastuzumab Emtansine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[38]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[39]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Trastuzumab Emtansine caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[37]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[40]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Levomilnacipran.	Chronic pain [MG30]	[41]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Regorafenib.	Colorectal cancer [2B91]	[42]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Vilazodone.	Depression [6A70-6A7Z]	[41]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Vortioxetine.	Depression [6A70-6A7Z]	[41]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Trastuzumab Emtansine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Cannabidiol.	Epileptic encephalopathy [8A62]	[42]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[42]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Trastuzumab Emtansine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[37]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[44]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Trastuzumab Emtansine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[45]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[46]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[47]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Trastuzumab Emtansine and Idelalisib.	Mature B-cell leukaemia [2A82]	[48]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[49]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Ibrutinib.	Mature B-cell lymphoma [2A85]	[50]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Ponatinib.	Mature B-cell lymphoma [2A85]	[49]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Panobinostat.	Multiple myeloma [2A83]	[37]
Nepafenac	DMYK490	Moderate	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Nepafenac.	Osteoarthritis [FA00-FA05]	[51]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Trastuzumab Emtansine and MK-4827.	Ovarian cancer [2C73]	[42]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Trastuzumab Emtansine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[52]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Trastuzumab Emtansine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[37]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Trastuzumab Emtansine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[37]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Trastuzumab Emtansine and Cabozantinib.	Thyroid cancer [2D10]	[53]
-----------


⏷ Show the Full List of 28 DDI Information of This Drug

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
4	Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14.
5	Trastuzumab emtansine. An inadequately assessed combination of two cytotoxic drugs. Prescrire Int. 2014 Dec;23(155):289.
6	The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
7	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
8	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
9	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
10	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
11	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
12	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
13	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
14	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
15	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
16	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
17	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
18	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
19	Drug Interactions Flockhart Table
20	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
21	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
22	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
23	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
24	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
25	Different functions between human monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem. 2008 Aug;315(1-2):113-21.
26	Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism. J Pharmacol Exp Ther. 2010 Mar;332(3):755-63.
27	Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
28	Analysis of the substrate-binding site of human carbonyl reductases CBR1 and CBR3 by site-directed mutagenesis. Chem Biol Interact. 2009 Mar 16;178(1-3):234-41.
29	Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
30	In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
31	Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
32	Instability of C154Y variant of aldo-keto reductase 1C3. Chem Biol Interact. 2017 Oct 1;276:194-202.
33	Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
34	Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.
35	Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
36	Hormonal properties of norethisterone, 7alpha-methyl-norethisterone and their derivatives. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):213-22.
37	Cerner Multum, Inc. "Australian Product Information.".
38	European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
39	Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.
40	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
41	Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
42	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
43	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
44	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
45	Canadian Pharmacists Association.
46	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
47	Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
48	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
49	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
50	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
51	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
52	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
53	Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]